JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

Search

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.34 2.45

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.26

Max

3.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-24M

-154K

Pardavimai

-32M

19M

P/E

Sektoriaus vid.

7.48

37.461

Pelno marža

-0.825

Darbuotojai

119

EBITDA

-24M

-939K

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+68.71% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

240M

617M

Ankstesnė atidarymo kaina

0.89

Ankstesnė uždarymo kaina

3.34

Naujienos nuotaikos

By Acuity

50%

50%

148 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-26 23:52; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-26 23:52; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2025-10-26 23:46; UTC

Rinkos pokalbiai

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

2025-10-26 23:41; UTC

Rinkos pokalbiai

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

2025-10-26 23:34; UTC

Uždarbis

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

2025-10-26 23:32; UTC

Uždarbis

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

2025-10-26 23:30; UTC

Uždarbis

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

2025-10-26 22:29; UTC

Uždarbis

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

2025-10-26 22:29; UTC

Uždarbis

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

2025-10-26 22:29; UTC

Uždarbis

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

2025-10-26 22:29; UTC

Uždarbis

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

2025-10-26 22:16; UTC

Uždarbis

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

2025-10-26 21:33; UTC

Įsigijimai, susijungimai, perėmimai

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

2025-10-26 19:29; UTC

Įsigijimai, susijungimai, perėmimai

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

2025-10-26 06:39; UTC

Uždarbis

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

2025-10-26 06:39; UTC

Uždarbis

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

2025-10-26 06:39; UTC

Uždarbis

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

2025-10-24 21:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-24 21:24; UTC

Rinkos pokalbiai

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025-10-24 21:07; UTC

Uždarbis

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025-10-24 20:58; UTC

Uždarbis

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025-10-24 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-24 20:40; UTC

Uždarbis

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025-10-24 20:24; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:23; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:13; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 20:07; UTC

Rinkos pokalbiai

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025-10-24 19:40; UTC

Rinkos pokalbiai

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025-10-24 19:35; UTC

Rinkos pokalbiai

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025-10-24 19:33; UTC

Uždarbis

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

68.71% į viršų

12 mėnesių prognozė

Vidutinis 5.5 USD  68.71%

Aukščiausias 7 USD

Žemiausias 3.5 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

7

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

148 / 373 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat